Xyrem
Phase 3Completed 0 watching 0 views this week📈 Rising
74
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Narcolepsy With Cataplexy
Conditions
Narcolepsy With Cataplexy
Trial Timeline
Oct 1, 2014 → Jan 25, 2019
NCT ID
NCT02221869About Xyrem
Xyrem is a phase 3 stage product being developed by Jazz Pharmaceuticals for Narcolepsy With Cataplexy. The current trial status is completed. This product is registered under clinical trial identifier NCT02221869. Target conditions include Narcolepsy With Cataplexy.
Hype Score Breakdown
Clinical
27
Activity
18
Company
7
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02221869 | Phase 3 | Completed |
Competing Products
20 competing products in Narcolepsy With Cataplexy